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A BST R AC T   
 
Aim: To determine the resistance profile of Mycobacterium tuberculosis complex (MTBC) strains to 
first-line antituberculous drugs.  
Methods: A total of 138 patients with MTBC growth from 2008-2018 were evaluated retrospectively. 
The Ehrlich-Ziehl-Neelsen (EZN) staining method was used for direct smear preparations, the 
BACTEC MGIT 460 TB system the Lowenstein-Jensen medium for culture planting and the 
BACTEC NAP test for the diagnosis of MTBC. Susceptibility tests were performed using the 
BACTEC MGIT 460 TB system with the streptomycin, isoniazid, rifampicin and ethambutol (SIRE) 
kit in accordance with the manufacturer's recommendations.  
Results: Of the total 138 tuberculosis (TB) cases, 44 (31.9%) were female and 94 (68.1%) were male. 
MTBC was most frequently isolated from pulmonary specimens (90.6%). Acid-resistant bacilli 
(ARB) positivity was detected in 88 (63.8%) samples by EZN staining for culture-positive samples. 
In our study, without considering single or multiple drug resistance (MDR), total resistance rates in 
MTBC strains were determined for, isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and 
streptomycin (SM); 10.1%, 4.3%, 2.9%, and 12.3% respectively. While the susceptibility to all drugs 
was 82.6%, multiple drug–resistant tuberculosis (MDR-TB) was 2.9%. 
Conclusion: These results are important since they are the first data reported from our province 
regarding the determination of the resistance profile to anti-TB drugs. Resistance rates in our study 
were very close to the 2016 data average of the Ministry of Health of Turkey. Determination of TB 
resistance profiles, as well as proper and regular treatment, will contribute to the control of MDR-
TB. 
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Introduction 
Tuberculosis (TB) is a chronic, granulomatous 
disease caused by Mycobacterium tuberculosis 
complex (MTBC) [1,2]. Although TB mainly 
affects developing countries, it continues to be 
a public-health problem all over the world [3]. 
It is estimated that one-third of the world's 
population is latently infected with MTBC. The 
lifetime risk of developing active TB in 
individuals with latent TB infection is 5-15% 
[1,4].  
Mycobacteria cultures and the microscopic 
investigation of the presence of acid-resistant 
bacteria (ARB) with an Ehrlich-Ziehl-Neelsen 
(EZN) stain are the main diagnostic methods 
[5].  
Some first-line antituberculous (anti-TB) drugs 
used in the treatment of TB are isoniazid (INH), 
rifampicin (RIF), ethambutol (EMB), and 
streptomycin (SM). The Center for Disease 
Control and Prevention (CDC) and the World 
Health Organization (WHO) both recommend 
the combined use of first-line drugs in the initial 
treatment of TB. However, the problem of 
bacterial resistance to these anti-TB drugs is an 
important problem in Turkey, as well as in the 
rest of the world. Co-resistance of TB strains to 
INH and RIF, which are first-line anti-TB 
drugs, is defined as multidrug resistance [5].  
The aim of this study was to investigate INH, 
RIF, EMB and SM resistance rates of MTBC 
strains isolated from clinical specimens in the 
Microbiology Laboratories of Bolu Abant İzzet 
Baysal University Hospital between 2008 and 
2018. 
 
Methods 
Permission was obtained from the local clinical 
research and ethics committee (Decision no. 
2018/211) for this study. A total of 138 cases of 
MTBC growth from the samples sent to the 
medical     microbiology     laboratory   of   our  
 
hospital for mycobacteria culture from 2008-
2018 were retrospectively analyzed. The 
samples sent to the laboratory were subjected to 
homogenization and concentration after 
decontamination with the N-Acetyl-L-Cysteine 
(NALC)-Sodium Hydroxide (NaOH) method. 
The EZN staining method was used for ARB 
detection in direct smear preparations. In 
accordance with the recommendations of the 
manufacturer, mycobacteria cultures were 
inoculated on BACTEC MGIT 460 TB (Becton 
Dickinson, USA) and Lowenstein-Jensen 
media. The BACTEC NAP test was used to 
identify MTBC bacteria with growth in 
mycobacteria cultures. Susceptibility tests were 
performed with the BACTEC MGIT 460 TB 
system (Becton Dickinson, USA) using the 
streptomycin, isoniazid, rifampicin and 
ethambutol (SIRE) kit, according to the 
manufacturer's recommendations. The data are 
summarized in frequencies and percentages. 
 
Results  
Of the total 138 TB cases included in the study, 
44 (31.9%) were female and 94 (68.1%) were 
male, and the mean age was 48.4 ± 19.09 
(Figure 1). ARB positivity was detected in 88 
(63.8%) of the samples with MTBC culture 
growth (Figure 2). MTBC culture growths were 
most frequently isolated from the lungs of 
patients (90.6%). The Distribution of MTC 
strains by sample type is shown in Table 1. The 
monodrug resistance rates were found as 4.3% 
for isoniazid, 1.4% for rifampicin, 0.7% for 
ethambutol, and 8% for streptomycin. In our 
study, without considering single or multiple 
drug resistance (MDR), total resistance rates in 
MTBC strains were determined for isoniazid 
(INH), rifampicin (RIF), ethambutol (EMB), 
and streptomycin (SM); 10.1%, 4.3%, 2.9%, 
and 12.3% respectively. While the 
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susceptibility to all drugs was 82.6%, multiple 
drug-resistant tuberculosis (MDR-TB) was 
found 2.9% (Table 2). Of the total 138 TB 
cases, 128 (92.8%) were new cases while 10 
(7.2%) were previously  treated  cases.  One  of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the previously treated patients was MDR-TB. 
 
Discussion 
TB is one of the top ten causes of deaths in the 
world. In 2017, 1.6 million people were reported to  
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have died from TB [6]. The regions with the 
highest incidence of TB and the highest TB 
mortality in the world are Africa and Southeast 
Asia. Turkey, located in the WHO European 
region has an estimated incidence of 18 per 
100,000 and a mortality rate of 0.62 per 
100,000, according to the 2017 Global TB 
report lower rates than in Europe, which has an 
incidence rate of 32 per 100,000 and a mortality 
rate of 3.4 per 100,000 [7].  
Clinically, TB is seen in pulmonary (PTB) and 
extra-pulmonary (EPTB) forms. EPTB is the 
TB involving organs other than the lungs (e.g., 
pleura, lymph nodes, abdomen, genitourinary 
tract, skin, joints and bones, or meninges) [8]. 
In Turkey, according to the Tuberculosis 
Control 2018 report, 61.3% of all TB cases 
were PTB, 33.6% were EPTB, and 5.1% were 
PTB+EPTB [7]. The results of our study (PTB 
90.6%, EPTB 9.4%) differ from this data and 
instead resemble the results of the study 
conducted by Çiftçi et al. [9] (PTB 87.4%, 
EPTB 12.6%) which stated that the EPTB ratio 
in the European Union and European Economic 
Area ranged between 4% and 48% in 2011. 
Difficulties in sampling and diagnosing TB 
could explain this difference [10]. 
The determination of acid-resistant bacilli by 
microscopy is one of the most important 
methods in the diagnosis of TB and the 
detection of infectious cases [5]. It is a simple, 
rapid, inexpensive, and specific method for the 
diagnosis of TB, but it has a low sensitivity. 
Direct-preparation sensitivity has been reported 
to range from 22-78% [11]. These values are 
known to vary with individual factors, such as, 
the bacterial genus, the number of bacilli in the 
sample, decontamination, concentration 
processes, the spreading thickness, and the 
experience of the microbiologist [12]. The ARB 
positivity rate found in our study (63.8%) is 
similar to the average of the data in our country 
(59.8%) [7].  
Culture is still accepted as the gold standard of 
TB diagnosis. It only requires 10 tuberculosis 
bacilli per milliliter of sputum to obtain a 
positive result from a culture, making it more 
sensitive than microscopy. It also allows 
antibiotic susceptibility tests and the 
identification of mycobacteria species [13].  
The most intractable difficulty of TB treatment 
is the natural drug resistance of MTBC, which 
has a tough, multi-layered cell wall and 
effective multi-drug efflux pumps. In addition, 
it can acquire drug resistance due to 
inappropriate treatment regimens and various 
mutations in chromosomal genes caused by 
treatment noncompliance limiting the 
availability of an already-small number of 
drugs [14]. In Turkey’s 2018 tuberculosis 
control report while 78.6% of the strains were 
susceptible to all drugs tested, the total 
resistance rates for INH, RIF, SM, and ETM 
were found 11.9%, 4.2%, 3.7% and 10.6%, 
respectively [7]. Other Turkish studies found 
rates ranging between 6.4-20.1% for INH, 4.1-
9% for RIF, 72-83.1% for EMB, 2.1-11.1% for 
SM, and 72-83.1% for all drug-sensitive 
isolates that have been reported [5,11,15-17]. In 
our study, while 82.6% of the strains were 
susceptible to all drugs tested, the total 
resistance rates for INH, RIF, ETM, and SM 
were 10.1%, 4.3%, 2.9% and 12.3% 
respectively which are consistent with the 2016 
data average of the Ministry of Health [7]. 
Consistent with our study in the European 
region, the sensitivity rate to all first-line drugs 
was reported to be 85.6% [18]. Second-line 
anti-TB drugs with more toxic side effects in 
addition to treatment with first-line drugs, 
negatively affects both patient compliance and 
the prolongation of treatment duration [19]. The 
reasons for the emergence of clinically resistant 
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TB include the following: treatment errors, the 
non-use of standard drug regimens, inadequate 
drug combinations and dosages, irregular drug 
use, drug additions to a non-healing regimen, 
low-dose drug use, gastrointestinal absorption 
problems, and expired or appropriate-condition 
errors, such as the use of non-stored drugs [20]. 
According to WHO data, approximately 10.4 
million people were infected with TB in 2016. 
3.5% of newly diagnosed cases and 18% of 
previously treated patients are MDR-TB. [16]. 
Some studies from Turkey found the rate of 
MDR-TB to be 2.8-5.7% [3,5,11,14-17,21]. 
The resistance rate of 2.9% found in our study 
seems to be consistent with the data of the 
Turkish Ministry of Health 2016 (3.3%) [7].  
 
Conclusion  
We think that our results are important since 
they are the first data reported from our 
province regarding the determination of the 
resistance profile against anti-TB drugs. Our 
resistance rates are very close to the 2016 data 
average of the Ministry of Health of Turkey. In 
addition to the diagnosis of TB, the study of 
susceptibility tests to anti-TB drugs is 
important for the treatment efficacy. It is known 
that irregular treatment in patients who have 
been treated previously can cause MDR-TB 
development. Therefore, determination of 
resistance profiles in TB cases, as well as 
appropriate and regular treatment, will 
contribute to the control of TB. 
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